Skip to content
2000
  1. Home
  2. A-Z Publications
  3. The International Journal of Gastroenterology and Hepatology Diseases
  4. Volume 1, Issue 2
  5. Article
Volume 1, Issue 2
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Background

is highly endemic in the Mediterranean Basin, including Egypt. Despite attempts to control the disease in Egypt, there are still significant problems with diagnostic accuracy. The prevalence and incidence of are unknown and we have uncertain predictive prognostic tests for treatment results. Identification of the actual epidemiological burden of in Egypt, and levels of the antibody titer among rural and urban populations is critical to the evaluation of combined treatment approaches that achieve lesser relapse rates.

Objective

To determine the current prevalence of infections in Egypt and changes in its epidemiological pattern.

Methods

We compared the available diagnostic yield, sensitivity, specificity, accuracy, cost, and time consumption of serological tests with those from quantitative polymerase chain reaction (qPCR) to establish their ability to meet the diagnostic criteria. Also, we conducted surveillance of the rates of infection in both humans and animals.

Results

The enzyme-linked immunosorbent assay (ELISA) and blood cultures were less sensitive diagnostic methods for the detection of These approaches are technically challenging and have a high likelihood of false negatives. Therefore, they are best reserved for suspected cases with negative standard agglutination test (SAT).

Conclusion

A more practical approach to the diagnosis of depends on epidemiological testing for risk factors, clinically suspected cases, and SAT titers ≥ 1/320. Strategies to prevent relapsing include: 1) Health education of patients, 2) Long-term triple therapy, ., three months, with possible extension to six months in severe or recurrent cases or when complications occur.

© 2022 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/2666290601666220721104600
2022-09-01
2025-03-02

  • From This Site

    /content/journals/ijghd/10.2174/2666290601666220721104600
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FrancoM.P. MulderM. GilmanR.H. SmitsH.L. Human Brucellosis.Lancet Infect. Dis.200771277578610.1016/S1473‑3099(07)70286‑4 18045560
     [Google Scholar]
  2. WassifS.M. ElsamaraG.H. ElsabbaaghF. Brucellosis in Sharkia governorate: An epidemiological study.Egypt. J. Community Med.19921011147158
     [Google Scholar]
  3. SouthwickF. Infectious Diseases: A Clinical Short Course.New YorkMcGraw-Hill Medical2008344347
     [Google Scholar]
  4. SalataR.A. Cecil Medicine.PhiladelphiaSaunders Elsevier201218911892
     [Google Scholar]
  5. IsturizR. GotuzzoE. Tropical infectious disease concerns in pregnancy.Tropical Infectious Diseases. GuerrantR. WalkerD. WellerP. Elsevier Churchill Livingstone200617081721
     [Google Scholar]
  6. HadadiA. RasoulinejadM. HajiAbdolbaghi, M.; Mohraz, M.; Khashayar, P. Clinical profile and management of Brucellosis in Tehran - Iran.Acta Clin. Belg.2009641111510.1179/acb.2009.004 19317236
     [Google Scholar]
  7. GulH.C. ErdemH. Brucellosis (Brucella species).Principles and Practice of Infectious Diseases. MandellG.L. BennettJ.E. DolinR. PhiladelphiaChurchill Livingston201525842589
     [Google Scholar]
  8. Abd ElaalM.A. Current status of Brucella infections in a major referral fever hospital In Egypt.2013
     [Google Scholar]
  9. BeechingN. MadkourM. Manson’s Tropical Diseases.LondonWB Saunders Elsevier Ltd2013
     [Google Scholar]
  10. Al DahoukS. NeubauerH. HenselA. SchönebergI. NöcklerK. AlpersK. MerzenichH. StarkK. JansenA. Changing epidemiology of human Brucellosis, Germany, 1962-2005.Emerg. Infect. Dis.200713121895190010.3201/eid1312.070527 18258041
     [Google Scholar]
  11. TörökE. CookeF. MoranE. Bacteria.Oxford Handbook of Infectious Diseases and Microbiology. TorokE. CookeF. MoranE. UKOxford University Press2017207364
     [Google Scholar]
  12. YangX. Brucellosis.Conn’s Current Therapy. E-Book: Expert Consult. Imprint. BopeE.T. KellermanR.D. Saunders20168183
     [Google Scholar]
  13. PappasG. AkritidisN. BosilkovskiM. TsianosE. Brucellosis.N. Engl. J. Med.2005352222325233610.1056/NEJMra050570 15930423
     [Google Scholar]
  14. PappasG. AkritidisN. TsianosE. Effective treatments in the management of Brucellosis.Expert Opin. Pharmacother.20056220120910.1517/14656566.6.2.201 15757417
     [Google Scholar]
  15. PappasG. MarkoulaS. SeitaridisS. AkritidisN. TsianosE. Brucellosis as a cause of carpal tunnel syndrome.Ann. Rheum. Dis.200564579279310.1136/ard.2004.028944 15834067
     [Google Scholar]
  16. PappasG. SoleraJ. AkritidisN. TsianosE. New approaches to the antibiotic treatment of Brucellosis.Int. J. Antimicrob. Agents200526210110510.1016/j.ijantimicag.2005.06.001 16039098
     [Google Scholar]
  17. AndersonN. KoshyA. RossK. Bacterial, fungal and parasitic diseases of nervous system.Bradley’s Neurology in Clinical Practice. JankovicJ. MazziottaJ. PomeroyS. DaroffR. Amsterdam, NetherlandsElsevier201611471158
     [Google Scholar]
  18. YoungE. Brucella species (Brucellosis).Principles and Practice of Pediatric Infectious Diseases. LongS. PickeringL. ProberC. Amsterdam, NetherlandsElsevier201286186410.1016/B978‑1‑4377‑2702‑9.00163‑X
     [Google Scholar]
  19. ShehataG.A. Abdel-BakyL. RashedH. ElaminH. Neuropsychiatric evaluation of patients with Brucellosis.J. Neurovirol.2010161485510.3109/13550280903586386 20151851
     [Google Scholar]
  20. AkritidisN. TzivrasM. DelladetsimaI. StefanakiS. MoutsopoulosH.M. PappasG. The liver in Brucellosis.Clin. Gastroenterol. Hepatol.2007591109111210.1016/j.cgh.2006.08.010 17482524
     [Google Scholar]
  21. CaballeriaE. MassoR.M. AragoJ.V. SanchisA. Ascites as the first manifestation of Brucella granulomatous hepatitis.J. Hepatol.199215341541610.1016/0168‑8278(92)90080‑9 1447508
     [Google Scholar]
  22. TeschkeR. DananG. Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): Diagnostic algorithm based on the quantitative roussel uclaf causality assessment method (RUCAM).Diagnostics (Basel)202111345810.3390/diagnostics11030458 33800917
     [Google Scholar]
  23. RealM. BarnhillM.S. HigleyC. RosenbergJ. LewisJ.H. Drug-induced liver injury: Highlights of the recent literature.Drug Saf.2019423365387
     [Google Scholar]
  24. SargesP. SteinbergJ.M. LewisJ.H. Drug-induced liver injury: Highlights from a review of the 2015 literature.Drug Saf.2016399801821
     [Google Scholar]
  25. ShahbazO. MahajanS. LewisJ.H. Highlights of drug - and herb- induced liver injury in the literature from 2016: How best to translate new information into clinical practice?Expert Opin. Drug Metab. Toxicol.2017139935951
     [Google Scholar]
  26. TuohutaerbiekeM. LiX. YinY. ChenW. WuD. MaoZ. MamuerjiangJ. MaoY. ShenT. The characteristics, prevalence, and risk factors of drug-induced liver injury among Brucellosis inpatients in Xinjiang, China.Front. Pharmacol.20211265780510.3389/fphar.2021.657805 34040524
     [Google Scholar]
  27. UrbanT.J. DalyA.K. AithalG.P. Genetic basis of drug-induced liver injury: Present and future.Semin. Liver Dis.201434212313310.1055/s‑0034‑1375954 24879978
     [Google Scholar]
  28. AndradeR.J. RoblesM. UlzurrunE. LucenaM.I. Drug-induced liver injury: Insights from genetic studies.Pharmacogenomics20091091467148710.2217/pgs.09.111 19761370
     [Google Scholar]
  29. ChenM. BorlakJ. TongW. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.Hepatology201358138839610.1002/hep.26208 23258593
     [Google Scholar]
  30. BjörnssonE.S. Epidemiology, predisposing factors, and outcomes of drug-induced liver injury.Clin. Liver Dis.202024111010.1016/j.cld.2019.08.002 31753242
     [Google Scholar]
  31. TeschkeR. LarreyD. MelchartD. DananG.A-O. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: Rucam and the role of novel diagnostic biomarkers such as microRNAs.Medicines (Basel)2016331810.3390/medicines3030018
     [Google Scholar]
  32. TeschkeR.A-O. EickhoffA. BrownA.C. NeumanM.G. SchulzeJ.A-O. Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: Tricky dilemma after EMA correctly and officially retracted letter of support.Int. J. Mol. Sci.201921121210.3390/ijms21010212
     [Google Scholar]
  33. TeschkeR. Idiosyncratic DILI: Analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019.Front. Pharmacol.201910730
     [Google Scholar]
  34. BenichouC. DananG. FlahaultA. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge.J. Clin. Epidemiol.1993461113311336
     [Google Scholar]
  35. DananG. BenichouC. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries.J. Clin. Epidemiol.199346111331330
     [Google Scholar]
  36. DananG. TeschkeR. RUCAM in drug and herb induced liver injury: The update.Int. J. Mol. Sci.20151711410.3390/ijms17010014
     [Google Scholar]
  37. DananG. TeschkeR. Roussel Uclaf causality assessment method for drug-induced liver injury: Present and future.Front. Pharmacol.20191085310.3389/fphar.2019.00853 31417407
     [Google Scholar]
  38. TeschkeR. ZhuY. JingJ. Herb-induced liver injury in Asia and current role of Rucam for causality assessment in 11,160 published cases.J. Clin. Transl. Hepatol.20208220021410.14218/JCTH.2020.00009 32832401
     [Google Scholar]
  39. TeschkeR. WolffA. FrenzelC. SchwarzenboeckA. SchulzeJ. EickhoffA. Drug and herb induced liver injury: Council for international organizations of medical sciences scale for causality assessment.World J. Hepatol.201461173210.4254/wjh.v6.i1.17 24653791
     [Google Scholar]
  40. GuptaA. BansalR. GuptaV. Tuberculosis, loprosy and Brucellosis.Ophthalmology.4th ed YanoffM. DukerJ. Amsterdam, NetherlandsElsevier2014716719
     [Google Scholar]
  41. YoungE.J. An overview of human Brucellosis.Clin. Infect. Dis.199521228328910.1093/clinids/21.2.283 8562733
     [Google Scholar]
  42. PatelN. BottoneE.J. Gastrointestinal tract infections.Cases in Medical Microbiology and Infectious Diseases.3rd ed GilliganP. SmileyM.L. ShapiroD.S. Washington, D.C.American Society for Microbiology Press2014157254
     [Google Scholar]
  43. BeechingN. CorbelM. Brucellosis.Harrison’s Principles of Internal Medicine.19th ed KasperD. FauciA. HauserS. LongoD. JamesonJ. LoscalzoJ. New YorkMcGraw Hill2015857861
     [Google Scholar]
  44. TorresA. MenndeyR. WunderinkR. Pyogenic bacterial pneumonia and lung abscess.Murray and Nadel’s Textbook of Respiratory Medicine.5th ed MasonR. BroaddusV. MartinT. KingT. SchraufnageD. MurrayJ. NadelJ. Amsterdam, NetherlandsElsevier201069974010.1016/B978‑1‑4160‑4710‑0.00032‑8
     [Google Scholar]
  45. VollerA. BartlettA. BidwellD.E. Enzyme immunoassays with special reference to ELISA techniques.J. Clin. Pathol.197831650752010.1136/jcp.31.6.507 78929
     [Google Scholar]
  46. FerriF. Diseases and disorders.Ferri’s Clinical Advisor; Mo.: Elsevier Mosby. FerriF.F. St. Louis2010161162
     [Google Scholar]
  47. Alişkan, H. The value of culture and serological methods in the diagnosis of human Brucellosis.Mikrobiyol. Bul.2008421185195 18444578
     [Google Scholar]
  48. SchutzeG. JacobsR. Brucella.Nelson Textbook of Pediatrics.20th ed KliegmanR. GemeJ. SchorN. Amsterdam, NetherlandsElsevier201614191420
     [Google Scholar]
  49. Işeri, S.; Bulut, C.; Yetkin, M.A.; Kinikli, S.; Demiröz, A.P.; Tülek, N. Comparison of the diagnostic value of blood and bone marrow cultures in Brucellosis.Mikrobiyol. Bul.2006403201206 17001849
     [Google Scholar]
/content/journals/ijghd/10.2174/2666290601666220721104600
Loading
Molecular and Serological Testing for Brucellosis in Egypt
Int J Gastroenterol Hepatol Dis 1, e210722206948 (2022); https://doi.org/10.2174/2666290601666220721104600
/content/journals/ijghd/10.2174/2666290601666220721104600
/content/journals/ijghd/10.2174/2666290601666220721104600
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Review Article
Keyword(s): Brucellosis; doxycycline; relapse; rifampin; serological testing; standard agglutination test (SAT)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test